Summary
The provided FDA label excerpts only address restricted use for proven/strongly suspected susceptible bacterial infections. Most claims (e.g., mechanisms, indications, dosing durations, side effects, pediatric age limits, and dosing frequency) are not supported or contradicted by the supplied label text, so overall alignment cannot be established from the excerpts.
Category Scores
Accurate Statements
Doxycycline for injection should be used only to treat or prevent infections proven or strongly suspected to be caused by susceptible bacteria; prescribing otherwise is unlikely to provide benefit and increases risk of drug resistance.
INDICATIONS AND USAGE: “doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.” PRECAUTIONS (General): “Prescribing ... in the absence of proven or strongly suspected bacterial infection ... increases the risk of the development of drug-resistant bacteria.”
Unsupported Statements
Doxycycline is frequently considered a drug of choice for various bacterial infections.
No support in the supplied label excerpts.
Doxycycline has broad-spectrum activity against many Gram-positive and Gram-negative bacteria and atypical organisms.
No support in the supplied label excerpts.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
No support in the supplied label excerpts.
Doxycycline is well-absorbed orally.
The supplied excerpts are about doxycycline for injection; no oral absorption information provided.
Doxycycline has a long half-life that allows for once or twice daily dosing.
No pharmacokinetic/dosing-frequency information provided in the supplied excerpts.
Doxycycline penetrates well into tissues.
No support in the supplied label excerpts.
Doxycycline is often the initial treatment of choice for Lyme disease (early localized, early disseminated, and late Lyme disease).
No Lyme indications provided in the supplied label excerpts.
Doxycycline is a preferred agent for treating Rocky Mountain spotted fever.
No Rocky Mountain spotted fever indications provided in the supplied label excerpts.
Doxycycline is a preferred agent for treating ehrlichiosis.
No ehrlichiosis indications provided in the supplied label excerpts.
Doxycycline is a preferred agent for treating anaplasmosis.
No anaplasmosis indications provided in the supplied label excerpts.
Doxycycline is a recommended option for community-acquired pneumonia, particularly for atypical pathogens such as Mycoplasma pneumoniae and Chlamydophila pneumoniae.
No community-acquired pneumonia indications provided in the supplied label excerpts.
Doxycycline is indicated for treating sexually transmitted infections like chlamydia.
No sexually transmitted infection/chlamydia indications provided in the supplied label excerpts.
Doxycycline is indicated for treating sexually transmitted infections like gonorrhea.
No sexually transmitted infection/gonorrhea indications provided in the supplied label excerpts.
Common side effects of doxycycline include gastrointestinal upset such as nausea, vomiting, and diarrhea.
No adverse reaction information provided in the supplied label excerpts.
Doxycycline can cause photosensitivity, an increased sensitivity to sunlight.
No photosensitivity information provided in the supplied label excerpts.
Patients taking doxycycline are advised to take precautions to avoid sunburn.
No sun/photoprotection instructions provided in the supplied label excerpts.
Doxycycline can cause tooth discoloration in developing fetuses and young children.
No pediatric/pregnancy dental adverse effect information provided in the supplied label excerpts.
Use of doxycycline is generally avoided in children younger than 8 years old unless other medications are not suitable.
No pediatric age restriction information provided in the supplied label excerpts.
More serious, less common side effects of doxycycline can include esophageal irritation.
No esophageal irritation information provided in the supplied label excerpts.
Doxycycline can increase the risk of Clostridioides difficile-associated diarrhea.
No C. difficile warning information provided in the supplied label excerpts.
For early Lyme disease, doxycycline treatment typically lasts 14 to 21 days.
No Lyme dosing/duration information provided in the supplied label excerpts.
For Rocky Mountain spotted fever, doxycycline treatment may range from 7 to 21 days.
No Rocky Mountain spotted fever dosing/duration information provided in the supplied label excerpts.
For community-acquired pneumonia, doxycycline treatment is usually continued for at least 5 to 7 days after symptom resolution.
No community-acquired pneumonia dosing/duration information provided in the supplied label excerpts.
For chlamydia, doxycycline is typically treated with a 7-day course.
No chlamydia dosing/duration information provided in the supplied label excerpts.
Doxycycline is available as a generic medication.
No information on generic availability provided in the supplied label excerpts.
Contradictions
Important Omissions
The AI claims many specific indications, dosing regimens (durations), adverse reactions, and population restrictions, but the supplied label excerpts do not cover these topics; therefore, key label-supported details cannot be verified.
Importance:
High
No label-supported administration instructions for the injection formulation were provided/assessed (e.g., IV-only specifics).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Many claims (indications/durations/side effects/pediatric restrictions) are not supported by the provided label excerpts. While the excerpted safety message about restricted use supports resistance avoidance, unsupported dosing and population/clinical-effect statements could mislead if relied upon.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Unaligned
Primary Issue
Most statements are not supported or contradicted by the supplied FDA label excerpts.
Suggested Improvement
Limit claims to what is explicitly supported by the provided label text (restricted use for proven/strongly suspected susceptible bacterial infections) unless the full doxycycline for injection prescribing information is supplied for evaluation.